(3RS)-3-[N-Benzyl-((2S)-2-hydroxy-3-phenoxypropyl)-amino]butyric Acid Methyl Ester | 259799-48-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3RS)-3-[N-Benzyl-((2S)-2-hydroxy-3-phenoxypropyl)-amino]butyric Acid Methyl Ester
• 英文别名: methyl 3-[benzyl-[(2S)-2-hydroxy-3-phenoxypropyl]amino]butanoate
• CAS: 259799-48-9
• 化学式: C₂₁H₂₇NO₄
• 分子量: 357.45
• InChiKey: UIIONEMUYAZNJK-NNBQYGFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
  申请人：McDonald J. Joseph

  公开号：US20050209278A1

  公开（公告）日：2005-09-22

  This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A 1 , A 2 , Y, E 1 , E 2 , E 3 , and R x are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.

  这项发明通常涉及蛋白酶抑制剂（也称为“蛋白酶”），更具体地涉及哌啶基和哌嗪基磺酰甲基羟肟酸，该类化合物在结构上抑制基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP”）活性和/或聚集素酶活性。这类羟肟酸通常对应以下结构式： （其中A1、A2、Y、E1、E2、E3和Rx如本说明书中所定义），还包括这类化合物的盐。这项发明还涉及这类羟肟酸的组合物、合成这类羟肟酸的中间体、制备这类羟肟酸的方法，以及治疗与MMP活性和/或聚集素酶活性相关的疾病（特别是病理性疾病）的方法。
• Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
  申请人：Fujisawa Pharmaceutical Co. Ltd.

  公开号：US20030181726A1

  公开（公告）日：2003-09-25

  This invention relates to new aminoalcohol derivatives or salts thereof represented by the following formula [I]: 1 wherein each symbol is as defined in the specification or salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.

  该发明涉及由以下式表示的新氨基醇衍生物或其盐：1其中每个符号如规范中定义或其盐，具有肠道选择性交感兴奋剂、抗溃疡、抗胰腺炎、脂解作用、抗尿失禁和抗排尿活性，以及其制备方法、包含相同的药物组合物，以及用于预防和/或治疗规范中指示的疾病的方法，适用于人类或动物。
• AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1107944A1

  公开（公告）日：2001-06-20
• [EN] AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS<br/>[FR] DERIVES D'AMINOALCOOL ET LEUR UTILISATION COMME AGONISTES DU RECEPTEUR BETA-3-ADRENERGIQUE
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2000012462A1

  公开（公告）日：2000-03-09

  This invention relates to new aminoalcohol derivatives or salts thereof represented by formula (I) wherein each symbol is as defined in the specification or salts thereof which have β3 adrenergic agonist activity and therefore have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment of diseases indicated in the specification to a human being or an animal.